nach oben

Urolithiasis

Erschienen in:

29.11.2018 | Preface

Empirical therapy or precision medicine for kidney stone formers in the ‘-omics’ era?

verfasst von: Giovanni Gambaro

Erschienen in: Urolithiasis | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

Identifying specific molecules and cellular pathways involved in the pathogenesis of a given patient’s disease is the key to developing personalized drugs addressing such targets. Patient genotyping is often needed to discover these specific molecular targets. Recent technological advances have been making it easier, quicker, and cheaper to genotype individual patients, letting us glimpse the feasibility of a medicine tailored to every single patient. …

Palsson R et al (2019) Genetics of common complex kidney stone disease: insights from genome-wide association studies. Urolithiasis (current issue)

Wang X, Lieske JC (2018) Heritable traits that contribute to nephrolithiasis. Urolithiasis. https://doi.org/10.1007/s00240-018-1095-1 CrossRefPubMed

Hill F, Sayer JA (2018) Precision medicine in renal stone-formers. Urolithiasis. https://doi.org/10.1007/s00240-018-1091-5 CrossRefPubMedPubMedCentral

Halbritter J, Baum M, Hynes AM, Rice SJ, Thwaites DT, Gucev ZS, Fisher B, Spaneas L, Porath JD, Braun DA, Wassner AJ, Nelson CP, Tasic V, Sayer JA, Hildebrandt F (2015) Fourteen monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis. J Am Soc Nephrol 26:543–551CrossRefPubMed

Braun DA, Lawson JA, Gee HY, Halbritter J, Shril S, Tan W, Stein D, Wassner AJ, Ferguson MA, Gucev Z, Fisher B, Spaneas L, Varner J, Sayer JA, Milosevic D, Baum M, Tasic V, Hildebrandt F (2015) Prevalence of monogenic causes in pediatric patients with nephrolithiasis or nephrocalcinosis. Clin J Am Soc Nephrol 11:664–672CrossRef

Daga A, Majmundar AJ, Braun DA, Gee HY, Lawson JA, Shril S, Jobst-Schwan T, Vivante A, Schapiro D, Tan W, Warejko JK, Widmeier E, Nelson CP, Fathy HM, Gucev Z, Soliman NA, Hashmi S, Halbritter J, Halty M, Kari JA, El-Desoky S, Ferguson MA, Somers MJG, Traum AZ, Stein DR, Daouk GH, Rodig NM, Katz A, Hanna C, Schwaderer AL, Sayer JA, Wassner AJ, Mane S, Lifton RP, Milosevic D, Tasic V, Baum MA, Hildebrandt F (2018) Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis. Kidney Int 93:204–213CrossRefPubMed

Goldfarb DS (2019) Empiric therapy of kidney stones. Urolithiasis (current issue)

Ferraro PM, D’Addessi A, Gambaro G (2013) When to suspect a genetic disorder in a patient with renal stones, and why. Nephrol Dial Transplant 28:811–820CrossRefPubMed

Rhodes HL, Yarram-Smith L, Rice SJ, Tabaksert A, Edwards N, Hartley A, Woodward MN, Smithson SL, Tomson C, Welsh GI, Williams M, Thwaites DT, Sayer JA, Coward RJ (2015) Clinical and genetic analysis of patients with cystinuria in the United Kingdom. Clin J Am Soc Nephrol 10:1235–1245CrossRefPubMedPubMedCentral

10.

Oliveira B et al (2019) Inherited proximal tubular disorders and nephrolithiasis. Urolithiasis (current issue)

11.

Faller N, Dhayat NA, Fuster DG (2018) Nephrolithiasis secondary to inherited defects in the thick ascending loop of henle and connecting tubules. Urolithiasis. https://doi.org/10.1007/s00240-018-1097-z CrossRefPubMed

12.

Vezzoli G, Macrina L, Magni G, Arcidiacono T (2018) Calcium-sensing receptor: evidence and hypothesis for its role in nephrolithiasis. Urolithiasis. https://doi.org/10.1007/s00240-018-1096-0 CrossRefPubMed

13.

Dindo M, Conter C, Oppici E, Ceccarelli V, Marinucci L, Cellini B (2018) Molecular basis of primary hyperoxaluria: clues to innovative treatments. Urolithiasis. https://doi.org/10.1007/s00240-018-1089-z CrossRefPubMed

14.

Sas DJ et al (2019) Recent advances in the identification and management of inherited hyperoxalurias. Urolithiasis. https://doi.org/10.1007/s00240-018-1093-3 CrossRefPubMed

15.

Sahota A et al (2019) Cystinuria: genetic aspects, mouse models, and a new approach to therapy. Urolithiasis. https://doi.org/10.1007/s00240-018-1101-7 CrossRefPubMed

Titel: Empirical therapy or precision medicine for kidney stone formers in the ‘-omics’ era?
verfasst von: Giovanni Gambaro
Publikationsdatum: 29.11.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Urolithiasis / Ausgabe 1/2019
Print ISSN: 2194-7228
Elektronische ISSN: 2194-7236
DOI: https://doi.org/10.1007/s00240-018-1099-x

Neu im Fachgebiet Urologie

25.04.2024 | Nierenkarzinom | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Empirical therapy or precision medicine for kidney stone formers in the ‘-omics’ era?

Excerpt

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Heritable traits that contribute to nephrolithiasis

Living kidney donation from people at risk of nephrolithiasis, with a focus on the genetic forms

Recent advances in the identification and management of inherited hyperoxalurias

Urinary proteome in inherited nephrolithiasis

Empiric therapy for kidney stones

Inherited proximal tubular disorders and nephrolithiasis

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie